Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRICKET: Encorafenib + Cetuximab Retreatment in BRAF V600E mCRC
NCT06578559Phase 2Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, KL-140 in colorectal cancer (CRC), sponsored by Gruppo Oncologico Nord Ovest. Started Jul 2024; status: completed.
02
Drugs
encorafenibKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06578559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578559.